Cardiome Pharma (NASDAQ: CRME) picked a bad day for good news.
According to the AP the company announced "interim midstage data showed its experimental drug vernakalant was safe and effective in treating abnormal heart rhythm, compared with placebo"
CRME shares are up 47% on the news trading 4.6 million shares well ahead of average daily volume of 600,000.
The company has somewhat troubling financials. For the September quarter, CRME lost $31.6 million compared to $12.3.
Revenue fell from $2.4 million in Q3 2006 to $1 million.
The company had $84.4 of cash at the end of the quarter. All the numbers are Canadian dollars.
In other words, CRME does not have a significant amount of cash given its burn rate.
Douglas A. McIntyre
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
